Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey
Peter Mohr, Sebastian Haferkamp, Andreas Pinter, et al.
Advances in Therapy (2018) Vol. 36, Iss. 1, pp. 101-117
Open Access | Times Cited: 20

Showing 20 citing articles:

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
Howard L. Kaufman, Sophia Z. Shalhout, Gail Iodice
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 50
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Julia Maria Ressler, Matthias Karasek, Lukas Koch, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 2, pp. e001701-e001701
Open Access | Times Cited: 37
An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions
Cecilia Larocca, Nicole R. LeBoeuf, Ann W. Silk, et al.
American Journal of Clinical Dermatology (2020) Vol. 21, Iss. 6, pp. 821-832
Closed Access | Times Cited: 36
Advances in Targeting Cutaneous Melanoma
Dimitri Kasakovski, Marina Skrygan, Thilo Gambichler, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2090-2090
Open Access | Times Cited: 24
Observational Study of Talimogene Laherparepvec use for Melanoma in Clinical Practice in the United States (COSMUS-1)
Matthew Perez, Jonathan S. Zager, Thomas Amatruda, et al.
Melanoma Management (2019) Vol. 6, Iss. 2
Open Access | Times Cited: 27
Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma
Karyn Haitz, Hasan Khosravi, Jennifer Y. Lin, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 1, pp. 189-196
Closed Access | Times Cited: 27
Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
A. Fröhlich, Dennis Niebel, Simon Fietz, et al.
Cancer Immunology Immunotherapy (2020) Vol. 69, Iss. 5, pp. 759-769
Open Access | Times Cited: 26
Looking into a Better Future: Novel Therapies for Metastatic Melanoma
Alessia Villani, Massimiliano Scalvenzi, Gabriella Fabbrocini, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 3, pp. 751-767
Open Access | Times Cited: 23
Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment
Nikhil I. Khushalani, Kevin J. Harrington, Alan Melcher, et al.
Molecular Therapy — Oncolytics (2023) Vol. 31, pp. 100729-100729
Open Access | Times Cited: 6
Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis
Emma H. A. Stahlie, Evalyn E.A.P. Mulder, Sophie J. M. Reijers, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 175, pp. 103705-103705
Open Access | Times Cited: 9
A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
Alexander C.J. van Akkooi, Sebastian Haferkamp, Sophie Papa, et al.
Advances in Therapy (2020) Vol. 38, Iss. 2, pp. 1245-1262
Open Access | Times Cited: 14
An evaluation of talimogene laherparepvec for the treatment of melanoma
Kristy K. Broman, Jonathan S. Zager
Expert Opinion on Biological Therapy (2019) Vol. 20, Iss. 1, pp. 9-14
Closed Access | Times Cited: 10
Observational Study Of Talimogene Laherparepvec Use in the Anti-PD-1 era for Melanoma in the US (COSMUS-2)
James Sun, Brian Gastman, Lucy McCahon, et al.
Melanoma Management (2020) Vol. 7, Iss. 2, pp. 5-8
Open Access | Times Cited: 7
Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database
Karly S. Louie, Victoria Banks, Florian Scholz, et al.
Future Oncology (2020) Vol. 16, Iss. 8, pp. 317-328
Open Access | Times Cited: 6
External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort
Emma H. A. Stahlie, Michael J. Carr, Jonathan S. Zager, et al.
Annals of Surgical Oncology (2021) Vol. 29, Iss. 3, pp. 1637-1644
Closed Access | Times Cited: 6
Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma
Viola Franke, P.M.G. Smeets, Jacqueline E. van der Wal, et al.
Melanoma Research (2020) Vol. 30, Iss. 6, pp. 548-551
Closed Access | Times Cited: 5
Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlled trials
Shen Yuchun, Ya-Li Huang, Yi‐No Kang, et al.
Melanoma Research (2024) Vol. 35, Iss. 1, pp. 60-66
Closed Access
Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis
Kailan Sierra-Davidson, Aikaterini Dedeilia, Aleigha Lawless, et al.
Annals of Surgical Oncology (2024)
Open Access
Talimogene laherparepvec

Reactions Weekly (2019) Vol. 1739, Iss. 1, pp. 233-233
Closed Access | Times Cited: 1
Talimogene Laherparepvec (T-VEC)
Marcin Zdzienicki, Piotr Rutkowski, Evalyn E.A.P. Mulder, et al.
Springer eBooks (2021), pp. 265-277
Closed Access | Times Cited: 1
Page 1

Scroll to top